Jazz Pharmaceuticals

News

Jazz opts in to Zymeworks HER2 drug for $325m upfront

Jazz Pharma has lost little time in deciding to buy into Zymeworks' HER2-directed bispecific antibody zanidatamab, paying $325 million upfront for rights to the drug just weeks after taking

R&D

Competition is on the horizon for costly narcolepsy treatmen...

People who live with narcolepsy — about one out of every 2,000 Americans — don’t have many options when it comes to treatment.

News

NICE’s track record in cancer drugs: the impact of the CDF and the role of interim funding

Jazz and Zymeworks enter exclusive zanidatamab agreement

Jazz Pharmaceuticals and Zymeworks, Inc. have announced that Jazz and Zymeworks BC, Inc.

News

Jazz adds first immuno-oncology drug via $1.3bn Werewolf dea...

Jazz Pharma has bolstered its pipeline of cancer drugs through a $1.3 billion licensing agreement with Werewolf Therapeutics that adds its first immuno-oncology candidate.

News

Jazz breaks ground on $100m UK plant for cannabinoid drugs

Jazz Pharma has started construction of a manufacturing facility in the UK that will be used to manufacture cannabinoid drugs from its recently

News

Wales is first UK country to fund GW's Epidyolex for tuberou...

Patients in Wales with a rare disease that causes epilepsy will be the first in the UK to get access to GW Pharma's cannabis-based medicine Epidyolex, after the drug was cleared for use by

Jazz opts in to Zymeworks HER2 drug for $325m upfront

Competition is on the horizon for costly narcolepsy treatmen...

Jazz and Zymeworks enter exclusive zanidatamab agreement

Jazz adds first immuno-oncology drug via $1.3bn Werewolf dea...

Jazz breaks ground on $100m UK plant for cannabinoid drugs

Wales is first UK country to fund GW's Epidyolex for tuberou...

Recordati gets €10.9bn takeover bid from private equity firm

Using AI-driven synthetic personas to take your insights fur...

Jazz Pharmaceuticals

Editor's Picks